drugset / Trial / NCT00679094

Bowman-Birk Inhibitor Concentrate in Healthy Men

NCT00679094 ↗

Phase 1 Completed 20 enrolled National Cancer Institute (NCI)
RandomizedSingle-groupDouble-blindPrevention

Summary

This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Bowman-Birk inhibitor concentrate may prevent cancer.

Timeline

Start
2007-06
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bowman-Birk inhibitor concentrate Unknown — Oral

Indications

No indication recorded.